Jefferies analyst Maury Raycroft initiated coverage of Cue Biopharma with a Buy rating and $6 price target. The company’s novel IL-2 platform aims to improve on first generation IL-2 safety and efficacy, the analyst tells investors in a research note. The firm says CUE-101 has shown early but promising data while Cue also has an autoimmune platform that will garner more attention and could potentially attract partner interest.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CUE:
